Janux Therapeutics (NASDAQ:JANX) Trading 8% Higher

Janux Therapeutics, Inc. (NASDAQ:JANX) traded up 8% during mid-day trading on Thursday . The stock traded as high as $33.58 and last traded at $33.58. 439 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 227,858 shares. The stock had previously closed at $31.09.

Several analysts recently issued reports on the company. HC Wainwright began coverage on Janux Therapeutics in a research note on Tuesday, July 6th. They issued a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research cut Janux Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 9th. Cowen began coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set an “outperform” rating on the stock. Evercore ISI began coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set an “outperform” rating and a $35.00 price objective on the stock. Finally, Bank of America began coverage on Janux Therapeutics in a research report on Tuesday, July 6th. They set a “buy” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $35.00.

The company’s fifty day moving average is $30.09.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Tuesday, August 10th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.48). Equities analysts predict that Janux Therapeutics, Inc. will post -1.02 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. Woodline Partners LP purchased a new position in shares of Janux Therapeutics during the second quarter valued at approximately $8,340,000. Samsara BioCapital LLC purchased a new position in shares of Janux Therapeutics during the second quarter valued at approximately $15,168,000. Logos Global Management LP purchased a new position in shares of Janux Therapeutics during the second quarter valued at approximately $13,651,000. Millennium Management LLC purchased a new position in shares of Janux Therapeutics during the second quarter valued at approximately $1,878,000. Finally, BVF Inc. IL purchased a new position in Janux Therapeutics in the 2nd quarter worth approximately $29,358,000. Hedge funds and other institutional investors own 59.46% of the company’s stock.

Janux Therapeutics Company Profile (NASDAQ:JANX)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Recommended Story: Conference Calls and Individual Investors

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.